Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: A randomized clinical trial

Digestive Diseases and Sciences

Volumn 51, Issue 9, 2006, Pages 1595-1601

  Pratha, Vijaya ^a   Hogan, Daniel L ^a   Lynn, Richard B ^b   Field, Brian ^b   Metz, David C ^c  

^a Clinical Applications Laboratories   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Basal acid output; GERD; Intravenous pantoprazole; Maximal acid output

Indexed keywords

ANTACID AGENT; ATTAPULGITE; PANTOPRAZOLE; PENTAGASTRIN; PLACEBO;

ABDOMINAL PAIN; ACID SECRETION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE PAIN; MALE; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RHINITIS; SIDE EFFECT; SYMPTOMATOLOGY; SYNCOPE; TASTE DISORDER; UPPER RESPIRATORY TRACT INFECTION; VASODILATATION; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ALUMINUM HYDROXIDE; ANALYSIS OF VARIANCE; ANTI-ULCER AGENTS; BENZIMIDAZOLES; BODY WEIGHTS AND MEASURES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ESOPHAGITIS, PEPTIC; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; INFUSIONS, INTRAVENOUS; MAGNESIUM HYDROXIDE; MALE; MIDDLE AGED; OMEPRAZOLE; PLACEBO EFFECT; SEVERITY OF ILLNESS INDEX; SILICIC ACID; SULFOXIDES; TREATMENT OUTCOME;

EID: 33748600714     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9108-2     Document Type: Article

References (12)

1. Richter JE, Bochenek W (2000) Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 95:3071-3080
2. Kovacs TO, Wilcox CM, DeVault K, Miska D, Bochenek W (2002) Pantoprazole US GERD Study Group B. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. Aliment Pharmacol Ther 16:2043-2052
3. Richter JE, Fraga P, Mack M, Sabesin SM, Bochenek W (2004) Pantoprazole US GERD Study Group. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther 20:567-575
4. Metz DC, Bochenek WJ (2003) Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther 17:155-164
5. Metz DC, Pratha V, Martin P, Paul J, Maton PN, Lew E, Pisegna JR (2000) Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol 95:626-633
6. Hassan MA, Hobsley M (1970) Positioning of subject and of nasogastric tube during a gastric secretion study. Br Med J 1:458-460
7. Pratha V, Karlstadt R, Lynn RB, Lane JR, Hogan DL (2001) Gastric pH may not be an accurate indicator of gastric acidity. Am J Gastroenterol 96(Suppl):66
8. Pratha V, Lynn RB, Karlstadt R, Burton MS, Hogan DL (2003) Gastric pH above 2.5 is of limited use as a measure of acid inhibition. Am J Gastroenterol 98(Suppl):42
9. Wurzer H, Schutze K, Bethke T, Fischer R, Luhmann R, Riesenhuber C (1999) Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenousoral regimen. Austrian Intravenous Pantoprazole Study Group. Hepatogastroenterology 46:1809-1815
10. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W, Metz DC (2000) Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 118:696-704
11. van Rensburg CJ, Hartmann M, Thorpe A, Venter L, Theron I, Luhmann R, Wurst W (2003) Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer. Am J Gastroenterol 98:2635-2641
12. Morris J, Karlstadt R, Blatcher D, Field B, McDevitt M (2003) Intermittent intravenous pantoprazole rapidly achieves and maintains gastric pH greater than or equal to 4.0 compared with continuous infusion H2-receptor antagonist in intensive care unit patients. Crit Care Med 31:A34